Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413772 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CLK1DYRK1ADYRK1B | |
| SCHEMBL2412726 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4CCNT1CDK9APP | |
| SCHEMBL2417452 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4CLK1DYRK1ADYRK1B | |
| SCHEMBL2417457 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4CLK1DYRK1ADYRK1B | |
| Hydrochloric Acid SCHEMBL2549747 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CLK1DYRK1ADYRK1B | |
| SCHEMBL1023384 | 0.76 | CHRNB2 (0.48) | CHRNB2CHRNA4ESR1ESR2P2RY14 | |
| SCHEMBL1023383 | 0.76 | CHRNB2 (0.48) | CHRNB2CHRNA4ESR1ESR2P2RY14 | |
| Hydrochloric Acid SCHEMBL1072684 | 0.75 | CHRNB2 (0.47) | CHRNB2CHRNA4ESR1ESR2P2RY14 | |
| SCHEMBL3538504 | 0.72 | CDK9 (0.46) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL3538509 | 0.72 | CDK9 (0.46) | CHRNB2CHRNA4P2RY14CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367818-B1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | INITIATOR PHARMA AS (DK) | 2018-07-25 | — | — | EP | claimed |
| EP-2367818-A1 | 8-AZABICYCLO Ý3.2.1¨OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-09-28 | — | — | EP | claimed |
| WO-2010057848-A1 | 8-AZABICYCLO [3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | WO | claimed |
| EP-2367818-B1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | INITIATOR PHARMA AS (DK) | 2018-07-25 | — | — | EP | disclosed |
| US-8633218-B2 | 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | ANIONA APS (DK) | 2014-01-21 | — | — | US | disclosed |
| US-20110263640-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-10-27 | — | — | US | disclosed |
| EP-2367818-A1 | 8-AZABICYCLO Ý3.2.1¨OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010057848-A1 | 8-AZABICYCLO [3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263640-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | CHRNB2 57/4885CHRNA4 113/4885CLK1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.